TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: High Resolution Imaging of Cerebral Vasculature by Functional Micro-Doppler Sonography During Brain Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 6 and 65 years~* Patient follow-up in the Neurosurgery department for a partial drug-resistant epilepsy~* Etiological diagnosis certain or likely of DCF2~* Operating indication~* consent (or agreement of the legal representative) to participate in the study~Exclusion Criteria:~* Etiological diagnosis other than a DCF2~* Refusal of consent~* No health insurance

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Functional micro-Doppler sonography (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants having Eastern Co-operative Oncology Group (ECOG) Performance Status less than or equals to (\<=) 1~* Adequate hematological, hepatic and renal function as defined in the protocol~* Participant must have measurable disease of Multiple Myeloma (MM) and received greater than (\>) 3 prior lines of therapy for MM including a Proteasome Inhibitors (PI), an Immunomodulatory Imide Drug (IMiD) and an anti-CD38 mAb or who are refractory to at least PI agent (carfilzomib or bortezomib) and IMiD according to the International Myeloma Working Group (IMWG) criteria~* Participant must have documented evidence progressive disease as defined by the IMWG criteria either on or after their last regimen~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Any condition, including any uncontrolled disease state that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.~* An active second malignancy or evidence of disease of cancer (other than MM) before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).~* Cerebrovascular accident/stroke (\< 6 months prior enrollment) or neurologic instability per clinical evaluation due to tumor involvement of the Central Nervous System~* Diagnosis of fever within 1 week prior to study intervention administration~* Part B: Participants planning to undergo a stem cell transplant should not be enrolled to reduce disease burden prior to transplant.~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M3258 10 mg QD (Type: EXPERIMENTAL): None
- M3258 10 mg Twice per Week (Type: EXPERIMENTAL): None
- M3258 20 mg Twice per Week (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Pain Pen for Breakthrough Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable cancer pain requiring the equivalent of 60-1000 mg oral morphine/day~* 1-4 breakthrough pain episodes/day~* Patients must be able, in the opinion of the investigator, to fully comply with trial requirements~* Patients who have given written informed consent~Exclusion Criteria:~* Uncontrolled pain~* Women who are pregnant, lactating or intend to become pregnant~* Cardiopulmonary disease that would increase the risk of opioids~* Neurologic or psychiatric disease that would compromise data collection~* Recently started chemotherapy or radiotherapy in as far as it would be effective in lowering breakthrough pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Ependymoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ependymoma that is unlikely to respond to existing therapy and for which no curative therapy exists~* Evidence of residual tumor (\>= 5mm) by MRI scan performed within two weeks prior to study entry~* No brain stem tumors~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm3~* Platelet count greater than 50,000/mm3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal failure~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study~* No serious active infections or fever~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas)~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids for cerebral edema allowed (must be on stable dose for at least 1 week prior to study)~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patients 60 Years and Older Suffering From Mandibular Fractures Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years at the time of the injury~* Diagnosis of any kind of mandibular fracture~* Informed consent obtained, i.e.:~  * Ability to understand the content of the patient information/ informed consent form (ICF)~ * Willingness and ability to participate in the clinical investigation according to the Registry Plan (RP)~ * Signed and dated EC/IRB approved written informed consent OR For patients who are not able to provide independent written informed consent: Written consent provided according to defined and IRB/EC approved procedures~Exclusion Criteria:~* Patients with previous history of mandibular fractures or mandibular defects treated surgically~* Participation in any other medical device or medicinal product study within the previous months that could influence bone healing and the results of the present study in the opinion of the treating physician

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Mandibular Fracture (Type: None): Elderly patients of \> 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of sickle cell anemia (Hgb SS) or sickle-β0-thalassemia (Hgb Sβ0)~* Current episode of ACS, defined as a new lobar or segmental pulmonary infiltrate seen on a chest radiograph and two or more of the following findings:~  1. Temperature of 38.5°C or higher~ 2. Tachypnea (i.e., rapid breathing)~ 3. Dyspnea or increased work of breathing~ 4. Chest wall pain~ 5. Oxygen saturation of less than 90% in room air by pulse oximetry~* Current episode of ACS diagnosed in the 24 hours prior to study entry~* Ability to take medication in capsule form~Exclusion Criteria:~* Prior participation in this study~* Diagnosed with any medical condition that will likely be worsened by corticosteroid therapy, including any of the following conditions:~  1. Diabetes mellitus~ 2. High blood pressure~ 3. Esophageal or gastrointestinal ulceration or bleeding~ 4. Known avascular necrosis~* Diagnosis of ACS in the 6 months prior to study entry~* Treatment with oral or parenteral corticosteroid therapy for any reason in the 14 days prior to study entry~* Use of inhaled corticosteroids or systemic corticosteroids for respiratory illness in the 3 months prior to study entry~* Long-term lung condition that requires treatment with corticosteroids~* Participation in a program of chronic transfusions that ended fewer than 4 months ago. A program of chronic transfusions includes a regimen of serial simple or exchange transfusions given at least every 6 weeks for at least three consecutive transfusions for the prevention of SCD-related complications.~* Pregnant~* Treatment with any investigational drug in the 90 days prior to study entry~* History of either tuberculosis or a positive skin test for tuberculosis~* Known HIV infection or a current systemic fungal infection

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight of 40 kg or more~* Established diagnosis of partial epilepsy for at least 1 year~* Current treatment with at least one and no more than two antiepileptics (AEDs)~* At least 6 episodes of simple partial motor seizures, complex partial seizures, or secondarily generalized seizures for 2 months (56 days) during the baseline period (No seizure free interval for more than 3 weeks)~Exclusion Criteria:~* Diagnosis of status epilepticus or epilepsia partialis continua within 6 months~* Patients with generalized epileptic syndrome~* Current or previous history of non-epileptic seizures, including psychogenic seizures~* Current or previous history of any serious or medically relevant systemic disease, including clinically apparent hepatic disease, renal failure, malignant neoplasm, insulin-requiring diabetes mellitus, or any disorder~* Patients with clinical evidence of significant cardiac disease~* Current or past (within 1 year) major significant psychotic disorder~* Have an ALT (GPT) greater than 1.5 times the upper reference limit or total bilirubin above the upper reference limit at screening laboratory tests

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 003 (Type: PLACEBO_COMPARATOR): Placebo tablet twice daily for 12 weeks
- 002 (Type: EXPERIMENTAL): RWJ-333369 200 mg tablet twice daily for 12 weeks
- 001 (Type: EXPERIMENTAL): RWJ-333369 100 mg tablet twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A patient's study eye must meet the following criteria to be eligible for inclusion in the study:~* 18 years of age or older~* Signs and symptoms of DED~* Consent to treat with topical immunomodulator~* Willing and able to comply with clinic visits and study related procedures~* Willing and able to sign the informed consent form~Exclusion Criteria:~A patient who meets any of the following criteria will be excluded from the study:~* Patients under the age of 18.~* Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)~* Active infectious systemic disease~* Active infectious ocular or extraocular disease~* Altered nasolacrimal flow of either acquired, induced, or congenital origin~* Hypersensitivity to dexamethasone~* Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit~* Patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including NSAIDS)~* Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xiidra Only Group (Type: ACTIVE_COMPARATOR): Patients with dry eye disease Xiidra only
- Xiidra + Dextenza Group (Type: EXPERIMENTAL): Patients with dry eye disease Xiidra + Dextenza

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CBT as an Adjunct to SRIs in the Treatment of BDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16-65~* A diagnosis of DSM-IV BDD or its delusional variant (delusional disorder, somatic type)~* Ability to communicate meaningfully with the investigators~* Competent to provide written consent, if over 18 years old, or competent to provide written assent, if 16-17 years, 11 months~* Parental consent, if under 18 years old~* For phase two: must be on a stable therapeutic dose of one of the following SRI medications for at least 8 weeks: fluoxetine, fluvoxamine, venlafaxine, clomipramine, paroxetine, citalopram, or sertraline.~Exclusion Criteria:~* current or lifetime diagnosis of any DSM_IV psychotic disorder not attributable to delusional BDD, current or lifetime diagnosis of DSM-IV bipolar disorder,~* current or recent (within 2 months of study entry) DSM-IV alcohol or substance dependence or abuse,~* recent suicide attempt, or suicidal ideation that warrants consideration of hospitalization,~* need for inpatient or partial hospital treatment,~* use of any medication prescribed for the treatment of BDD other than SRIs, including tricyclic antidepressants, buspirone, or neuroleptics,~* presence of any significant and/or unstable medical condition,~* females who are pregnant or breast-feeding, or who are sexually active and not using adequate contraception.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Body dysmorphic disorder (Type: EXPERIMENTAL): Participants with body dysmorphic disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis from LSUHSC-SHreveport Rheumatologist of rheumatoid arthritis (RA), osteoarthritis (OA), or myositis~* stable medication for at least 3 months~* OA in weightbearing joints, and limited to non-advanced OA per Kellgren Lawrence grading~* cleared by rheumatologist for participation in high intensity training and blood flow restriction training~Exclusion Criteria:~* cardiovascular or other disease preventing exercise participation~* within past 6 months, have performed regular physical activity training or physical therapy~* one or more arthroplasty in weight-bearing joints~* taking more then 5mg of prednisone in past 3 months~* unable to perform timed up and go test, 10 meter walk test, or 6 minute walk test without more than supervision assistance; assistive devices can be used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Traditional High-Intensity Training (Type: EXPERIMENTAL): Participants will perform their training at \~70% of their 1-repetition maximum, as traditionally advocated in strengthening literature. Each of the diagnoses (RA, OA, myositis) will have a High-Intensity arm.
- Low Intensity plus Blood Flow Restriction Training (Type: EXPERIMENTAL): Participants will perform their training at \~30% of their 1-repetition maximum, and will have blood flow partially occluded (60-70%) to the training limb. Each of the diagnoses (RA, OA, myositis) will have a Low-Intensity plus Blood Flow Restriction arm.
- Control (Type: NO_INTERVENTION): Each of the diagnoses (RA, OA, myositis) will have a control arm. The control groups will be evaluated at time 0, 4 weeks, and 8 weeks but will not receive intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic (stage IV) renal cell carcinoma (RCC) predominately clear cell type~* Prior nephrectomy~* Available HLA-matched (8/8, 7/8) unrelated donor~* At least one prior immunotherapy; or immunotherapy + chemotherapy; or targeted therapy, for metastatic RCC.~* Adequate organ function~Exclusion Criteria:~* Prior allogeneic stem cell transplantation~* RCC with histology other than clear cell type~* History or presence of brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MUD treatment (Type: EXPERIMENTAL): NST using MUD for metastatic renal cell carcinoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Have cancer.~* Taking opioid therapy for continued intractable pain.~* Experiencing less bowel movement frequency compared to that before the opioid treatment.~* Must meet the protocol-definition of opioid-induced constipation.~Exclusion criteria:~* Gastrointestinal or pelvic disorders known to affect gastrointestinal functions or induce bowel transit disorder and ileus.~* Subjects, who in the investigator's opinion, have gastrointestinal dysfunction predominantly due to causes other than the use of opioids.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Alvimopan 0.25 mg/yday (Type: EXPERIMENTAL): None
- Alviompan 0.5 mg/day (Type: EXPERIMENTAL): None
- Alvimopan 1 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Measuring sVAP-1 as a Predictor of Pregnancy Problems

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female participants who are in early pregnancy (\<20 weeks gestational age).~* 16 years and above~* Patient consents to take part in the study~Exclusion Criteria:~* Patient declines to be involved in the study~* Unsuccessful venepuncture

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pregnant women (Type: None): Women aged 16+ in early pregnancy (before 20 weeks of gestation).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility